30 closest matches · ranked by relevance
Polypharmacy
Primary: Number of Participants With Changes in Signs and Symptoms Related to Adverse Effects of Prescribed Medicines. Clinical Gains and Benefits to Residents — 17 Participants
Breast Neoplasms
Primary: Number of Participants With Factors Considered to Affect the Safety and/or Efficacy of Exemestane — 126; 324; 372; 68 participants
Seizures
Primary: Drug (Valproic Acid or Carbamazepine) Metabolite Profiles in Urine — 15.2; 13.1; 1.15; 2.13 nmol per mg creatinine
Non-small Cell Lung Cancer
Primary: Number of Participants With Adverse Drug Reactions — 1858; 518 Participants
Rheumatoid Arthritis
Primary: Total Number of Patients With Adverse Events — 27.8 Percentage of Patients
Acute Pain · Dysmenorrhea
Primary: Percentage of Patients With an Incidence of Adverse Event (AE) Associated to Potential Liver Damage During the Clinical Evaluation of Patients — 0.0 Percentage of Patients
Gastrointestinal Stromal Tumors
Primary: Number of Participants With Treatment-Related Adverse Events — 450 Participants
Eosinophilic Esophagitis (EoE)
Primary: Part A (SAD): Number of Treatment Emergent Adverse Events (TEAEs) by Participant — 1; 0; 1; 2 Participants
HIV-1 Infection
Primary: Number of Participants Who Reported Unlisted Adverse Drug Reaction. — 0 participants
Ischemic Heart Disease · Angina Pectoris · Coronary Artery Disease
Primary: Number of Participants With Acute Scaffold Thrombosis (ST) — 0; 0; 0 participants
Acromegaly
Primary: Number of Participants With Treatment-Related Adverse Events — 89; 20 Participants
Non-tuberculous Mycobacterial Diseases · Tuberculosis · Inhibition of Disseminated Mycobacterium Avium Complex Disease Associated With HIV Infections
Primary: Number of Patients With Adverse Drug Reactions in This Surveillance — 16; 7 Participants
Hemophilia A
Primary: Number of Participants Who Discontinued the Use of Study Drug — 10; 5 Participants
Pulmonary Hypertension
Primary: Number of Participants With Treatment-Related Adverse Events — 448; 101 Participants
CCR5-tropic HIV-1 Infection
Primary: Percentage of Participants With Adverse Drug Reactions (ADRs) — 23.53 percentage of participants
Carcinoma, Renal Cell
Primary: Number of Participants With Treatment-Related Adverse Events — 1599 Participants
Hemophilia A
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 15; 59; 2; 7 participants
Essential Hypertension
Primary: Number of Participants Experiencing AEs or ADRs — 184; 59 Participants
Breast Cancer
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) — 25.24 Percentage of Participants
Rheumatoid Arthritis
Primary: Incidence of Adverse Drug Reactions (ADRs) — 33.3 Percentage of participants
Smoking Cessation
Primary: Risk Factors for the Frequency of Treatment Related Adverse Events - Gender. — 377; 336 participants — p=<0.001
Healthy Volunteers
Primary: Maximum Level of Sedation for Lorazepam 1 mg IM + ADASUVE 10 mg — 12.3 units on a scale
Plaque Psoriasis
Primary: Hypothalamic-Pituitary-Adrenal (HPA) Axis Response — 19; 6 Participants
Small for Gestational Age
Primary: Number of Participants With Treatment Related Adverse Events. — 44 participants
Type 2 Diabetes Mellitus
Primary: Percentage of Participants With Serious Adverse Events (SAEs) and Serious Adverse Drug Reactions (SADRs) — 0.15; 0.00 percentage of participants
Glioblastoma · Glioma · Astrocytoma
Primary: Number of Participants Experiencing Adverse Events (AEs) — 324 participants
Melanoma
Primary: Number of Participants Who Completed Treatment — 120 Participants
Severe Hepatic Impairment
Primary: Maximum Observed Plasma Concentration (Cmax) of Dacomitinib — 9.673; 7.389 nanogram per milliliter
Tuberculosis · Non-tuberculous Mycobacterial Diseases (Including MAC Disease)
Primary: Number of Participants With Treatment-Related Adverse Events — 387; 113 Participants
Hypertension
Primary: Unexpected Adverse Events — 0.58 Percentage of patients